PGRMC1在子宫内膜癌组织中的表达及其临床意义

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年05期 页码: 839-844 栏目: 论著（妇科肿瘤） 出版日期: 2019-02-01

Title: The expression and clinical significance of PGRMC1 in endometrial carcinoma

作者: 刘 淼; 齐 跃; 谭明子; 金 山; 刘娟娟; 叶秋霖; 李 潇; 刘 晴; 郝莹莹; 林 蓓
中国医科大学附属盛京医院妇产科，辽宁 沈阳 110004

Author(s): Liu Miao; Qi Yue; Tan Mingzi; Jin Shan; Liu Juanjuan; Ye Qiulin; Li Xiao; Liu Qing; Hao Yingying; Lin Bei
Department of Gynecology and Obstetrics，Shengjing Hospital Affiliated to China Medical University，Liaoning Shenyang 110004，China.

关键词: 子宫内膜癌; 孕激素膜受体1; 免疫组织化学; 临床病理参数

Keywords: endometrial carcinoma; PGRMC1; immunohistochemistry; clinicopathological parameters

分类号: R737.33

DOI: 10.3969/j.issn.1672-4992.2019.05.031

文献标识码: A

摘要: 目的：检测孕激素膜受体1（PGRMC1）在子宫内膜癌组织中的表达，探讨其表达与子宫内膜癌的临床病理参数、预后的关系及其临床意义。方法：采用免疫组织化学SP法检测子宫内膜癌、子宫内膜不典型增生及正常子宫内膜组织中PGRMC1的表达，分析PGRMC1表达与子宫内膜癌的临床病理参数及患者预后的关系。结果：PGRMC1在子宫内膜癌组织中的阳性表达率最高（98.61%），明显高于子宫内膜不典型增生（62.07%）及正常子宫内膜组织（4.17%），P均<0.05。PGRMC1在Ⅰ型（雌激素依赖型）子宫内膜癌中的强阳性表达率（76.5%）明显高于Ⅱ型（非雌激素依赖型）（50.0%），P<0.05。PGRMC1的强阳性表达还与子宫内膜癌中ER、PR表达水平相关（P均<0.05）。PGRMC1的表达与FIGO分期、病理分级、淋巴结转移及浸润深度均未见明显相关性（P均>0.05）。PGRMC1表达虽与子宫内膜癌患者生存时间无明显相关，但在透明细胞癌中，PGRMC1强阳性表达的患者预后不良。Cox分析结果显示，FIGO分期晚、浸润深度≥1/2肌层是影响子宫内膜癌患者预后的独立危险因素。结论：PGRMC1在子宫内膜癌组织中的表达最高，与子宫内膜癌的发生相关。PGRMC1的强阳性表达与子宫内膜癌发病类型及ER、PR表达水平相关。PGRMC1强阳性表达的子宫内膜透明细胞癌患者的预后不良。

Abstract: Objective：To explore the relationship between expression of PGRMC1 and clinicopathological parameters，prognosis and the clinical significance of PGRMC1 by detecting the expression of PGRMC1 in different endometrial tissues.Methods：Expression of PGRMC1 in endometrial carcinoma，atypical hyperplasia endometrium，normal endometrium was detected by immunohistochemistry，and the relationship between PGRMC1 expression and clinicopathological parameters in endometrial carcinoma was analyzed.Results：The expression level of PGRMC1 in endometrial carcinoma（98.61%) was significantly higher than atypical hyperplasia and normal endometrium（62.07%，4.17%）(both P<0.05).The strong positive rate of PGRMCl in type Ⅰ was significantly higher than type Ⅱ（P<0.05).In endometrial carcinoma，the increase of PGRMC1 was detected in those with positive ER and PR status.However，the expression of PGRMC1 had no relationship with FIGO stage，pathological grades，vascular invasion and lymph node metastasis.The survival curve analysis showed that the overall prognosis of patients with endometrial carcinoma was unrelated to the expression of PGRMC1，but in clear cell endometrial carcinoma，strong positive expression of PGRMC1 could predict a poor prognosis，P<0.05.Follow the Cox regression model analysis，late FIGO stage，vascular invasion ≥1/2 could be the risk factors associated with the prognosis of endometrial carcinoma（P<0.05).Conclusion：The expression level of PGRMC1 was significantly increased in endometrial carcinoma，it is associated with the development of the endometrial carcinoma.The strong positive expression of PGRMC1 was associated with the type of endometrial carcinoma and status of ER，PR.Strong positive expression of PGRMC1 could predict a poor prognosis in clear cell endometrial carcinoma.

参考文献/REFERENCES

[1]Chen WQ, Zheng RS, Zhang SW, et al.Annual report on status of cancer in China, 2010 [J] .Chin J Cancer Res, 2014, 26(1): 48-58.
[2]Boll D, Karim-Kos HE, Verhoeven RH, et al.Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in the Netherlands: A population based study [J] .Eur J Obstet Gynecol Reprod Biol, 2013, 166: 209-214.
[3]Noer MC, Antonsen SL, Ottesen B, et al.Type I versus type Ⅱ endometrial cancer: Differential impact of comorbidity [J] .Int J Gynecol Cancer, 2018, 28(3): 1-8.
[4]Anne M Friela, Ling Zhanga, Cindy A Prub, et al.Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumor [J] .Cancer Lett, 2015, 356(200): 434-442.
[5]Randall ME, Filiaci VL, Muss H, et al.Randomized phase Ⅲ trial of whole-abdomial irradition versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study [J] .J Clin Oncol, 2006, 24(1): 36-44.
[6]Cahill MA.Progesterone receptor membrane component 1: An integrative review [J] .J Steroid Biochem Mol Biol, 2007(105): 16-36.
[7]Wen Ma, Xiangying Xia, Shufang Liang.The function of PRGMC1 and its role in tumorgenesis and tumor development [J] .Hans J Biomed, 2013, 3(2): 7-11.
[8]Ji Shufeng, Wu Aiguo, Yang Huafeng.Expression of progesterone receptor membrane component-1 is associated with the malignant phenotypes of breast cancer [J] .J South Med Univ, 2012, 32(5): 632-638.
[9]Lu Lin, Meng Wei, Guo Hongbo, et al.The silencing progesterone receptor membrane component-1 gene can inhibit the proliferation of endometrial carcinoma cell Ishikawa [J] .Guangdong Med J, 2010, 31 (15) : 1951-1953.
[10]Ikuo Kimura, Yoshiaki Nakayama, Morichika Konishi, et al.Functions of MAPR (membrane-associated progesterone receptor) family members as heme/steroid-binding proteins [J] .Current Protein and Peptide Science, 2012, 13(7): 687-696.
[11]Christiane Meyer, Roland Schmid, Peter C Scriba, et al.Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes [J] .Eur J Biochem, 1996, 239(3): 726-731.
[12]L□sel RM, Besong D, Peluso JJ, et al.Progesterone receptor membrane component 1-many tasks for a versatile protein [J] .Steroids, 2008, 73(9-10): 929-934.
[13]Hand RA, Craven RJ.Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells [J] .J Cell Biochem, 2003, 90(3): 534-547.
[14]Kowalik MK, Slonina D, Rekawiecki R, et al.Expression of progesterone receptor membrane component (PGRMC) 1 and 2, serpine binding protein 1 (SERBP1) and nuclear progesterone receptor (PGR) in the bovine endometrium during the estrous cycle and the first trimester of pregnancy [J] .Reprod Biol, 2013, 13(1): 15-23.
[15]Cheng GM,Zhang LY,Hao ZW,et al.Expression of PGRMC1 in different regions of fetal membrane and placenta tissue among women with premature rupture of fetal membrances [J] .J Zhengzhou University (Medical Sciences), 2016, 51(3): 378-381.
[16]Hughes AL, Powell DW, Bard M,et al.Dap1/PGRMC1 binds and regulates cytochrome p450 enzymes [J] .Cell Metab, 2007, 5(2): 143-149.
[17]Gerdes D, Wehling M, Leube B,et al.Cloning and tissue expression of two putative steroid membrane receptors [J] .Biol Chem, 1998, 379(7): 907-911.
[18]Neubauer H, Clare SE, Wozny W,et al.Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1 [J] .Breast Cancer Res, 2008, 10(5): 1-16.
[19]Mir SU, Ahmed IS, Amold S,et al.Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients [J] .Int J Cancer, 2012, 131(2): E1-9.
[20]Crudden G, Loesel R, Craven RJ.Overexpression of the cytochrome p450 activator HPR6 (heme-1 domain protein/human progesterone receptor) in tumors [J] .Tumour Biol, 2005, 26(3): 142-146.
[21]Peluso JJ, Liu X, Saunders MM, et al.Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1 [J] .J Clinical Endocrinology & Metabolism, 2008, 93(5): 1592-1599.
[22]Friel AM, Zhang L, Pru CA, et al.Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors [J] .Cancer Lett, 2015, 356(200): 434-442.
[23]Lu Lin, Shen Yuan, Meng Wei, et al.Inhibited progesterone receptor membrane component-1 by shRNA plasmid to increased drug sensitivity of endometrial carcinoma cell [J] .Chin J Cancer Prev Treat, 2012, 19(11): 814-817.
[24]Yu Li, Zeng Zhen, Liao Qinping, et al.The expression of PGRMC1 in endometrial cancer and its effect on endometrial cancer cell proliferation [J] .Chin J Human Sexuality, 2016, 25(4): 43-47.
[25]Caringella AM, Di Naro E, Loverro G.Clinical function of estrogen receptors in endometrial cancer [J] .Minerva Ginecol, 2011, 63(6): 495-504.
[26]Nachajova M, Mersakova S, Sivakova J,et al.New molecular aspects of endometrial carcinoma [J] .Neuro Endocrinol Lett, 2015, 36(7): 638-643.

[27]Neubauer H，Chen R，Schneck H，et al.New insight on a possible mechanism of progestogens in terms of breast cancer risk［J］.Horm Mol Biol Clin Investig，2011，6(1)：185-192.

备注/Memo: 盛京自由研究者计划（编号：201303）

更新日期/Last Update: 2019-02-01